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a b s t r a c t
A puriﬁcation process for the manufacture of a recombinant C-terminus heavy chain fragment from botulinum neurotoxin serotype C [rBoNTC(Hc)], a potential vaccine candidate, has been deﬁned and successfully scaled-up. The rBoNTC(Hc) was produced intracellularly in Pichia pastoris X-33 using a three step
fermentation process, i.e., glycerol batch phase, a glycerol fed-batch phase to achieve high cell densities,
followed by a methanol induction phase. The rBoNTC(Hc) was captured from the soluble protein fraction
of cell lysate using hydrophobic charge induction chromatography (HCIC; MEP HyperCel™), and then further puriﬁed using a CM 650M ion exchange chromatography step followed by a polishing step using
HCIC once again. Method development at the bench scale was achieved using 5–100 mL columns and
the process was performed at the pilot scale using 0.6–1.6 L columns in preparation for technology transfer to cGMP manufacturing. The process yielded approximately 2.5 g of rBoNTC(Hc)/kg wet cell weight (WCW) at the bench scale and 1.6 g rBoNTC(Hc)/kg WCW at the pilot scale. The puriﬁed
rBoNTC(Hc) was stable for at least 3 months at 5 and 80 °C as determined by reverse phase-HPLC and
SDS–PAGE and was stable for 24 months at 80 °C based on mouse potency bioassay. N-Terminal amino
acid sequencing conﬁrmed that the N-terminus of the puriﬁed rBoNTC(Hc) was intact.
Ó 2010 Elsevier Inc. All rights reserved.

Introduction
Clostridium botulinum produces seven antigenically distinct
neurotoxins differentiated serologically by speciﬁc neutralization
[1]. These botulinum neurotoxins (BoNT),1 designated as serotypes

⇑ Corresponding author. Fax: +1 402 472 4985.
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Abbreviations used: BCA, bicinchoninic acid; BoNT, botulinum neurotoxin; rBoNT,
recombinant botulinum neurotoxin; rBoNTC(Hc), recombinant botulinum neurotoxin
serotype C, heavy chain C-terminal fragment; BSA, bovine serum albumin; CV,
column volume; Hc, heavy chain C-terminal fragment; kDa, kilo-Dalton; MW,
molecular weight; PVDF, polyvinylidene diﬂuoride; SDS–PAGE, sodium dodecyl
sulfate–polyacrylamide gel electrophoresis; HCIC, hydrophobic charge induction
chromatography; HIC, hydrophobic interaction chromatography; WCW, wet cell
weight; TBS, tris base-buffered saline; PMSF, phenylmethylsulfonyl ﬂuoride; CGMP,
current Good Manufacturing Practices; PDS, puriﬁed drug substance; i.p., intraperitoneal; A280, protein absorbance at 280 nm; pI, isoelectric point; RP, reverse phase;
CM, carboxy methyl.
1
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A–G, are the most toxic natural substances known [2]. The BoNT
have been weaponized and are classiﬁed as a Category A select
agent by the National Institute of Allergy and Infectious Disease
[3]. There is a need for a safe, well characterized, and efﬁcacious recombinant vaccine that will protect against all seven known serotypes of the toxin as well as their subtypes [4,5]. The BoNT have
been extensively researched and are well characterized [6–11].
The heavy chain (Hc) fragments of BoNT (A–F) were shown to be
non-toxic, antigenic [11] and capable of eliciting a protective
immunity in vaccinated animals challenged with homologous
BoNT [12]. These results prompted an effort to develop a recombinant botulinum (rBoNT) vaccine against all seven serotypes using
the Hc fragments as vaccine antigens [10,13–17]. The Hc fragments
from each of the seven serotypes [rBoNT(Hc)] are distinctly different proteins with varying degrees of homology. Due to the differences in the characteristics of each protein and the level of
expression of each in Pichia pastoris, a standardized fermentation
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and puriﬁcation process was not feasible, resulting in the
development of separate processes for rBoNTA(Hc), rBoNTB(Hc),
rBoNTE(Hc) and rBoNTF(Hc) [14,16–18] and now rBoNTC(Hc).
Serotypes D and G are still under development.
During process development it was noted that rBoNTC(Hc) is
sensitive to proteolytic degradation during the puriﬁcation process. This was alleviated by the addition of protease inhibitors;
however, the use of protease inhibitors is not desirable in a current
Good Manufacturing Practice (cGMP) process. Proteolyic degradation of recombinant proteins expressed in P. pastoris can be problematic [19]. Alternative methods such as limiting growth rate
[20,21], manipulation of growth temperature [22,23] and addition
of protease inhibitors to the fermentation medium have been used
to reduce protease activity, but in the case of rBoNTC(Hc) these
manipulations proved to be unsuccessful, requiring a different approach. Analysis of in-process puriﬁcation samples by Western blot
and N-terminal sequencing indicated several truncated forms of
rBoNTC(Hc). The prominent forms were missing the ﬁrst 8 and
22 amino acids from the N-terminus based on the full length sequence listed in Table 1. Preliminary stability studies at 4 °C determined that the N-22 form was stable enough to move into process
development and scale-up. The potency of the N-22 rBoNTC(Hc)
was compared to the intact rBoNTC(Hc) produced with the aid of
protease inhibitors and was demonstrated to have similar potency
as compared to the intact rBoNTC(Hc) in a mouse potency assay.
Based on the potency results a new high copy rBoNTC(Hc) clone
was constructed using the truncated amino acid sequence and forwarded into process development.
This paper describes the research, development and scale-up of
a process to produce a N-22 rBoNTC(Hc) candidate vaccine suitable
for transfer to a cGMP facility for production of clinical material.
Two controlled non-CGMP pilot-scale runs were performed to
demonstrate scalability of the process.
Materials and methods
Molecular biology
A synthetic gene, codon optimized for P. pastoris, encoding the
rBoNTC(Hc) N-22 fragment was produced based on the native sequence of the C-terminus from the heavy chain domain of the
BoNT/C [5]. The full length sequence of the gene was synthesized
without the ﬁrst 22 amino acids from the N-terminus because of
degradation seen during early puriﬁcation development. The truncated gene was inserted into a pPICZA expression vector at the
EcoRI site. The pPICZA-truncated rBoNTC(Hc) was linearized with
SacI, transformed into P. pastoris X-33 generating Mut+ phenotypes,
as indicated by their growth on methanol plates, and clones were
selected on increasing amounts of Zeocin. Clones that contained

1–5 copies of the rBoNTC(Hc) were conﬁrmed by Southern blot,
grown under standard shake ﬂask conditions, induced with
methanol for 10 h and evaluated by Western blot. Results from
Western blot showed that there was a direct correlation between
increased gene copy number and increased intracellular expression
of rBoNTC(Hc).
Bench and pilot-scale fermentation
Fermentations were performed in 5 L fermentors (Bioﬂo 3000,
New Brunswick Scientiﬁc Edison, NJ) or in 19 L fermentors (NLF,
Bioengineering AG, Sagenrainstrasse 7, CH-8636 Wald, Switzerland) as described by Zhang et al. [21]. After a batch phase at pH
5.0 and 30 °C the cells were grown to the desired cell density by
feeding glycerol at a feed rate of 20 g/L/h for 6 h and transitioned
to methanol. Instead of using a standard exponential methanol
feed rate, the induction phase was performed using a methanol
sensor and feed-back control system with a set point of 2 mL/L
residual methanol for 9 h because of the limited methanol consumption of the rBoNTC(Hc) expressing clone. The methanol feed
solution contained 12 mL/L of PTM1 salts [24]. Samples of the
fermentation culture were periodically withdrawn for analyses in
order to determine the WCW and rBoNTC(Hc) production.
Bench-scale cell harvest and disruption
Cells were harvested by centrifugation at 11,300  g at 4 °C for
30 min using a Sorvall Evolution RC Centrifuge (Kendro Laboratory
Products, Asheville, NC). Cell paste was frozen at 80 °C until processed. Eighty grams of WCW were suspended in 400 mL of 50 mM
sodium phosphate, 2 M sodium chloride (NaCl), pH 6.5 to remove
residual fermentation medium. The cell suspension was centrifuged at 11,300  g at 4 °C for 5 min. Cell paste was resuspended
into the same amount of 50 mM sodium phosphate, 2 M NaCl,
pH 6.5 and homogenized using a Microﬂuidizer M-110EH
(Microﬂuidics Corp., Newton, CA) set at 22,000 psi with the lysate
chilled to <10 °C before processing. Two passes were required for
>90% cell disruption based on hemocytometer and soluble protein
released. The homogenate was clariﬁed at 11,300  g for 30 min at
4 °C followed by ﬁltration through a Pall AcroPak 200 with a 0.8/
0.2 lm Supor membrane (Pall Corp., East Hills, NY) and loaded
immediately onto the ﬁrst column.
Pilot-scale cell harvest and disruption
Cells harvested from a 19 L fermentation (10 L working volume)
were centrifuged at 11,300  g at 4 °C for 30 min using a Sorvall
Evolution RC Centrifuge (Kendro Laboratory Products, Asheville,
NC) and then stored at 80 °C until processed. One kilogram of

Table 1
N-Terminal sequence of puriﬁed rBoNTC(Hc) full length.
Sample

N-Terminal sequence

Intact rBoNTC(Hc)

pI of protein: 5.50
Protein MW: 52,370
Amino acid composition: A9 R17 N 61 D28 C1 Q12 E20 G27 H3 I51 L25 K26 M12 F27 P9 S35 T28 W8 Y30 V21
1 MTIPFNIFSY TNNSLLKDII NEYFNNINDS KILSLQNRKN TLVDTSGYNA EVSEEGDVQL
61 NPIFPFDFKL GSSGEDRGKV IVTQNENIVY NSMYESFSIS FWIRINKWVS NLPGYTIIDS
121 VKNNSGWSIG IISNFLVFTL KQNEDSEQSI NFSYDISNNA PGYNKWFFVT VTNNMMGNMK
181 IYINGKLIDT IKVKELGIN FSKTITFEIN KIPDTGLITS DSDNINMWIR DFYIFAKELD
241 GKDINILFNS LQYTNVVKDY WGNDLRYNKE YYMVNIDYLN RYMYANSRQI VFNTRRNNND
301 FNEGYKIIIK RIRGNTNDTR VRGGDILYFD MTINNKAYNL FMKNETMYAD NHSTEDIYAI
361 GLREQTKDIN DNIIFQIQPM NNTYYYASQI FKSNFNGENI SGICSIGTYR FRLGGDWYRH
421 NYLVPTVKQG NYASLLESTS THWGFVPVSE

N-Terminus of puriﬁed intact rBoNTC(Hc)
N-Terminus of puriﬁed N-22 rBoNTC(Hc)

TIPFNIFSYTNNSLL
YFNNI
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WCW was suspended in 5 L of 50 mM sodium phosphate, 2 M
NaCl, pH 6.5 and centrifuged at 11,300  g for 5 min and resuspended into the same amount of 50 mM sodium phosphate, 2 M
NaCl, pH 6.5 as a wash step. Cells were homogenized by two passes
through a Microﬂuidizer M-110EH (Microﬂuidics Corp., Newton,
CA) set at 22,000 psi. The homogenate was centrifuged at
11,300  g for 60 min at 4 °C and ﬁltered through a Pall AcroPak
1500, with a 0.8/0.2 lm Supor membrane (Pall Corp., East Hills,
NY) and loaded immediately onto the ﬁrst column.
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Bedford, MA). The CM 650M step was performed on a 1.02 L
(10 cm  20 cm) BPG 100/500 column (GE Healthcare Piscataway,
NJ). A polishing step was performed using a 650 mL MEP HyperCel™ (7 cm  10 cm) QS 70/500 column (Millipore, Bedford, MA).
Final product was dia-ﬁltered to pH 4.0 using 15 mM succinate,
pH 4.0 at 5 °C with a North Carolina SRT Model 10 ﬁltration unit
equipped with a 10 kDa Amersham Hollow ﬁber 5.2 ft2 membrane
(part #UFP-10-C-6A) (GE Healthcare Piscataway, NJ). Final product
was sterile ﬁltered with an AcroPak 200, with a 0.2 lm Fluorodyne
II membrane (Pall Corp., East Hills, NY) and stored at 2–8 °C.

Bench-scale puriﬁcation
All bench-scale chromatographic separations were performed
on a BioCad Workstation (Applied Biosystems, Foster City, CA)
at room temperature, with the load material on ice. A
2.7 cm  17.3 cm column (GE Healthcare Piscataway, NJ) packed
with 99 mL of MEP HyperCel™ resin (Pall Corp., East Hills, NY)
was equilibrated with ﬁve column volumes (CV) of 50 mM sodium
phosphate, 2 M NaCl, pH 6.5. Clariﬁed cell lysate was loaded at a
linear velocity of 300 cm/h followed by a 5 CV wash with the equilibration buffer. This was followed by a 5 CV 50 mM succinate, pH
4.5 wash and a 3 CV wash of 80% 50 mM succinate, pH 4.5, 20%
25 mM succinate, pH 3.0. Elution of the rBoNTC(Hc) was performed
by a 5 CV gradient from 70% 50 mM succinate, pH 4.5, 30% 25 mM
succinate, pH 3.0 to 20% 50 mM succinate, pH 4.5, 80% 25 mM succinate, pH 3.0 followed by a 3 CV hold step of 20% 50 mM succinate, pH 4.5, 80% 25 mM succinate, pH 3.0.
The product from the capture step was loaded directly onto a
2.7 cm  20.0 cm column (Applied Biosystems, Foster City, CA)
packed with 115 mL weak cation exchange CM 650M resin (Toso
Haas, Montgomeryville, PA). The column was equilibrated with 5
CV of 25 mM succinate, pH 4.0 at a linear velocity of 300 cm/h prior
to loading. After loading, a 1 CV wash was performed with the
equilibration buffer followed by a 3 CV wash of 35% 25 mM succinate, pH 4.0 and 65% 25 mM succinate 1 M NaCl, pH 4.0 buffer. The
elution proﬁle for this column was a 10 CV gradient from 65%
25 mM succinate 1 M NaCl, pH 4.0 buffer to 100% 25 mM succinate
1 M NaCl, pH 4.0 buffer. This was followed by a 5 CV hold step at
the end of the gradient to elute the remaining rBoNTC(Hc).
The CM 650M product was loaded directly onto a second
2.0 cm  17.5 cm (Waters Chromatography, Milford, MA) 55 mL
MEP HyperCel™ resin (Pall Corp., East Hills, NY) and equilibrated
with 5 CV of 50% 25 mM succinate, pH 4.0 and 50% 25 mM succinate 1 M NaCl, pH 4.0 at 300 cm/h. After loading, the column was
washed with 2 CV 50% 25 mM succinate 1 M NaCl, pH 4.0 and
50% 25 mM succinate, pH 3.0. rBoNTC(Hc) was eluted from the column using a 10 CV gradient from the 50% mix wash buffer to 30%
25 mM succinate 1 M NaCl, pH 4.0 and 70% 25 mM succinate, pH
3.0. This was followed by a 3 CV step of 15% 25 mM succinate
1 M NaCl, pH 4.0 and 85% 25 mM succinate, pH 3.0.
The ﬁnal product was dia-ﬁltered with 15 mM succinate, pH 4.0
using 10 kDa Molecular Weight Cut Off (MWCO) Amersham Hollow ﬁber 5.2 ft2 membrane (part #UFP-10-C-6A) (GE Healthcare
Piscataway, NJ) until the ﬁnal product reached a pH of 4.0. The
puriﬁed drug substance was sterile ﬁltered with an AcroPak 20,
with a 0.2 lm Fluorodyne II membrane (Pall Corp., East Hills, NY)
and stored at 80 °C.
Pilot-scale puriﬁcation
All chromatographic separations were performed using a North
Carolina SRT (Apex, NC) pilot-scale chromatography skid. All
chromatographic conditions were the same as the bench-scale
work, i.e., linear velocities, equilibration, washing and elution
methods. The MEP HyperCel™ capture step was performed using
a 1.08 L (10 cm  20 cm) Quickscale 100 column (Millipore,

Protein analysis
Total protein concentrations were determined using the BCA
(Pierce Chemical, St. Louis, MO) Standard Assay, using Bovine Serum Albumin (BSA) as a standard. Final product protein concentration was determined by A280 absorbance with an extinction
coefﬁcient of 1.75 [(mL/mg)  A280] based on amino acid analysis.
Purity was determined by a reducing SDS–PAGE using 10% Bis-Tris
gels with MOPS buffer system (Novex, San Diego, CA) stained with
Coomassie blue. Western blot analysis was performed using polyclonal rabbit anti-rBoNTC(Hc) antibody (produced by USAMRIID)
incubated at 0.05 lg/mL for 1–3 h at room temperature. The secondary antibody was a peroxidase labeled afﬁnity-puriﬁed goat
anti-rabbit IgG (Kirkegaard & Perry Laboratories, Gaithersburg,
MD) incubated at 0.025 lg/mL for 1 h at room temperature. The
SDS–PAGE-separated proteins were transferred to PVDF membranes (BioRad, Hercules, CA) at 25 V for 20 min, blocked with 5%
non-fat dry milk for 30 min and washed with tris base-buffered
saline (TBS) prior to treatment with antibodies. Blots were then
visualized by chemiluminescence using the ELC plus Detection
Kit (Amersham Pharmacia Biotech, Piscataway, NJ). N-Terminal
sequencing was performed by the University of Nebraska-Medical
Center Protein Core Facility using an ABI Procise 494 Sequencer
(Applied Biosystems, Foster City, CA).
The Biological Process Development Facility (BPDF) Quality
Control Laboratory (QCL) estimated quantity of rBoNTC(Hc) from
fermentation samples by HPLC using hydrophobic interaction
chromatography (HIC) with a 50 mm length TSK-gel Ether-5PW,
5 mm HIC column (Tosoh Bioscience, Montgomeryville, PA). Samples of 0.1 g of wet cell paste were suspended in 0.99 mL of cold
2 M sodium chloride with 5 lL of 4 °C 0.5 M EDTA in MilliQ adjusted to pH 8.3 with NaOH and 5 lL of 4 °C 0.2 PMSF in methanol
in a 2 mL centrifuge tube. To this mixture was added 3.8 g of cold
0.5 mm zirconia/silica beads (BioSpec Products, Bartlesville, OK).
The 2 mL centrifuge tube containing the mixture was loaded into
a Mini-Beadbeater (BioSpec Products, Bartlesville, OK) and
mechanically disrupted using ﬁve cycles for 1 min with 5 min rest
in a cold room. After the 5th cycle a small hole was poked into the
bottom of the 2 mL centrifuge tube using a hot 25G needle so as to
retain the beads. The 2 mL microcentrifuge tube was place in a
15 mL conical tube and spun for 5 min at 5000  g recovering the
lysate. The supernatant was transferred to a 2 mL microcentrifuge
tube and clariﬁed at 18,000  g for 10 min. The supernatants were
analyzed using a 0.8 mL/min gradient elution from 2 M sodium
chloride (in 50 mM sodium succinate, pH 4.5) to 0 M sodium chloride, over 11 min at 23 °C. Peak areas (280 nm) were compared to
that of a standard to estimate amounts in each injection. The BPDF
QCL estimated purity and quantity of rBoNTC(Hc) by HPLC using
Reverse Phase chromatography (RP) with a 75 mm length Bio-Suite
pPhenyl 1000, 10 mm RPC column (Waters, Milford, MA). Samples
were analyzed using a 1 mL/min gradient elution from 97% mobile
phase A (HPLC grade water with 0.1% formic acid) and 3% mobile
phase B (acetonitrile with 0.1% formic acid) to 3% mobile phase A
and 97% mobile phase B, over 40 min at 25 °C.
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Mouse potency bioassay

Results and discussion

The potency of puriﬁed rBoNTC(Hc) was determined using a
mouse potency bioassay [25]. Groups of 10 female mice (strain
Crl:CD-1 (Charles River, NC)) were intramuscularly vaccinated
twice (0 and 2 weeks) with the following doses of antigen, i.e.,
8.1, 2.7, 0.9, 0.3, 0.1, 0.033, and 0.011 lg rBoNTC(Hc)/mouse for a
total of 70 mice per assay. The antigen was formulated in 25 mM
sodium succinate, 15 mM sodium phosphate, 0.2% Alhydrogel™
(HCI Bio sector, Frederikssund, Denmark), 5% mannitol, pH 5.0.
Mice were challenged intramuscularly 3 weeks after the ﬁnal vaccination with 1000 mouse i.p. LD50 BoNT/C toxin complex. Mice
were observed twice daily for 5 days post-challenge. Results were
tabulated and analyzed using Probit analysis (SPSS, Chicago, IL).
These studies were conducted in compliance with the Animal Welfare Act and other Federal statutes and regulations relating to animals and experiments involving animals and adhere to principles
stated in the Guide for the Care and Use of Laboratory Animals of
the National Research Council (38a). The facility (USAMRIID)
where this research was conducted is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal
Care International.

Process development strategy
The strategy for developing a process to produce rBoNTC(Hc)
started by ﬁnding an optimal cell lysis buffer by screening different
pH and ionic strength buffers for release and solubility of
rBoNTC(Hc). After the optimal cell lysis buffer was identiﬁed, puriﬁcation development began by screening resins to capture the
rBoNTC(Hc). HIC and MEP HyperCel™ resins were selected for initial screening based on the characteristics of this protein and the
optimal lysis buffer developed for rBoNTC(Hc), i.e., high NaCl concentration (2 M). After the initial capture step was established subsequent chromatographic steps were developed based on speed of
processing, ease of scale-up, avoiding the requirement for buffer
exchange between chromatography steps, and the potential for
eventual cGMP scale-up. Given the susceptibility to proteolysis
and the desire for a rapid process with a minimum number of
steps, a signiﬁcant effort was made to identify chromatography
steps that were amenable to the previous elution buffers. A ﬁnal
diaﬁltration step exchanged the rBoNTC(Hc) into its ﬁnal storage
buffer.

Fig. 1. SDS–PAGE and Western blot (reduced) of HCIC equal volume column fractions. Lane 1, see blue plus 2 MW marker; lane 2, HCIC load; lane 3, HCIC ﬂow thru; lane 4,
HCIC pH 4.5 elution; lane 5, HCIC 80%/20% step elution; lane 6, HCIC elution product.

M.P. Dux et al. / Protein Expression and Puriﬁcation 75 (2011) 177–185

Bench and pilot-scale fermentation
The fermentation at both the 5 and 19 L scale produced
rBoNTC(Hc) at 7–10 mg rBoNTC(Hc)/g WCW as determined by HIC
HPLC as described above. Cells were stored at 80 °C prior to use.
Bench-scale puriﬁcation
Initially 2 mM phenylmethylsulfonyl ﬂuoride (PMSF) was
added to the cell suspension just prior to disruption to inhibit protease activity and prevent the formation of degradation products.
This helped to produce a non-degraded product, but after 24 h
degradation product products appeared when the puriﬁed bulk
material was stored at 2–8 °C. To further reduce the amount of
degradation another protease inhibitor, pepstatin, was added
during the second puriﬁcation step, which halted the degradation
of rBoNTC(Hc). N-Terminal sequencing was performed on the puriﬁed intact rBoNTC(Hc) and the puriﬁed degradation product.
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N-Terminal sequencing of the puriﬁed full length rBoNTC(Hc) indicated that the N-terminal methionine was missing and the puriﬁed
degraded product was missing the ﬁrst 22 amino acids from the Nterminus (Table 1). Both of these products were evaluated in a
mouse bioassay and were shown to be equally protective with an
ED50 (theoretical effective dose protecting half the mice) of approximately 102 ng. Based on the potency results and the desire not to
use protease inhibitors in a cGMP manufacturing process, a new
strain was constructed that incorporated the truncated rBoNTC(Hc)
gene excluding the ﬁrst 22 N-terminal amino acids.
Cell lysis buffer optimization studies evaluated different pH and
ionic strength concentrations. The optimal pH was between 6 and
7.5 and the amount of soluble rBoNTC(Hc) released from the cell
increased with increasing amounts of NaCl concentrations up to
2 M. The ﬁnal cell disruption buffer was 50 mM sodium phosphate
2 M NaCl, pH 6.5 buffer, which is ideal for binding to either a HIC or
a MEP Hypercel™ resin. Initially three passes through the Microﬂuidizer were performed as described in the section ‘Materials and

Fig. 2. The ﬁnal HCIC column chromatogram and SDS–PAGE (reduced) showing the separation of high molecular weight contaminants and degradation product are removed
across the elution of the rBoNTC(Hc) peak. Lane 1, see blue plus 2 MW marker; lane 2, HCIC load; lane 3, HCIC fraction 1; lane 4, HCIC fraction 2; lane 5, HCIC fraction 3
(product peak); lane 6, HCIC fraction 4; lane 7, HCIC fraction 5.
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methods’, but BCA, SDS–PAGE and Western blot results indicated
that two passes through the Microﬂuidizer yielded the same
amount of rBoNTC(Hc) as three passes. Two passes were also
advantageous since this reduced the total processing time of the
homogenization step, reducing the potential for proteolytic degradation of rBoNTC(Hc).
The rBoNTC(Hc) was puriﬁed at the bench-scale using ion exchange and hydrophobic charge induction chromatography techniques. Initially, an HIC resin was investigated to capture the
rBoNTC(Hc). Ether, butyl, octyl, and phenyl HIC resins were evaluated and only phenyl sepharose was able to bind rBoNTC(Hc) using
2 M NaCl. The rBoNTC(Hc) eluted continuously over a 10 CV gradient from 2 to 0 M NaCl and continued to elute at 0 M NaCl with the
peak not reaching baseline after an additional CV. Fifteen percent
glycerol was added to elution buffers, which did sharpen the
rBoNTC(Hc) peak slightly, but it still eluted from approximately
1.5 M NaCl to 0 M NaCl. Phenyl Sepharose did bind all of the
rBoNTC(Hc) at a load of 30 mg of total protein/mL resin with BoNTC(Hc) being approximately 5–10% of total protein. The phenyl
HIC product pool was subjected to further process development
using ion exchange, but regardless of the efforts lower MW degradation products and higher MW proteins were seen in down
stream puriﬁcation steps that proved to be very difﬁcult to separate from rBoNTC(Hc). Based on previous experience of purifying
BoNTE(Hc) with MEP HyperCel™ resin [18] we investigated capturing the rBoNTC(Hc) from the cell lysate with MEP HyperCel™ resin,
which is based on hydrophobic charge induction chromatography
(HCIC). The rBoNTC(Hc) was captured from the clariﬁed cell lysate,
which is in 50 mM sodium phosphate, 2 M NaCl, pH 6.5, by loading
directly on the MEP Hypercel™ resin. The rBoNTC(Hc) does not
elute off the HCIC resin until a pH of 4.2 in a 50 mM succinate buffer (Fig. 1). A step elution of 50 mM succinate at pH 4.5 prior to elution conditions was added and this enabled removal of 30% of the
total protein loaded onto the column with no rBoNTC(Hc) present
based on Western blot. This was followed by a 3 CV wash of 80%
50 mM succinate, pH 4.5, 20% 25 mM succinate, pH 3.0, which further separated some higher molecular weight proteins from the
rBoNTC(Hc). Elution was performed by a 5 CV gradient from 70%
50 mM succinate, pH 4.5, 30% 25 mM succinate, pH 3.0 to 20%
50 mM succinate, pH 4.5, 80% 25 mM succinate, pH 3.0. A gradient
elution was chosen to elute the rBoNTC(Hc) instead of a step elution because the product pool during step elution had a high protein concentration which caused some precipitation of the
rBoNTC(Hc). The maximum total protein loaded onto the capture
HCIC column was 30 mg/mL resin. The chromatogram from a
bench scale run along with the corresponding SDS–PAGE and Western blot are shown in Fig. 1.
Product from the capture column was directly loaded onto a CM
650M column which removed a majority of the larger molecular
weight Pichia host cell proteins that are present after the capture
step. Initially a resin screen was performed using cation and anion
exchange resins. It was found that rBoNTC(Hc) bound tightly to
strong cation exchange resins and could not be eluted at low pH,
and raising the pH across the pI, while the protein was bound to
the resin, caused some precipitation. It was also noticed that an increase in pH above the pI during dialysis (buffer exchange) caused
precipitation of rBoNTC(Hc). Thus, cation exchange methods were
no longer evaluated. A Toso Haas CM 650S (35 lm bead diameter)
anion exchange resin was determined to be most suitable for this
step, but due to process scale-up concerns, CM 650M (75 lm bead
diameter) was used instead because of the larger resin particle size.
In addition, there were only slight differences between the CM
650M and the CM 650S resin elution proﬁle. The elution gradient
was optimized from a 40 CV gradient from 100% 25 mM succinate,
pH 4.0 to 100% 25 mM succinate, 1 M NaCl, pH 4.0 to a 3 CV wash
step of 35% 25 mM succinate, pH 4.0 and 65% 25 mM succinate and

1 M NaCl, pH 4.0 and a 10 CV gradient from the above wash step to
100% 25 mM succinate and 1 M NaCl, pH 4.0 buffer. It was determined that increasing the column length from 15 to 20 cm improved separation of lower degradation product, but did not
remove all of them. Total protein load for this chromatography step
was optimized for 4 mg of total protein/mL of resin.
A second HCIC step was the most effective polishing step to remove degradation products of rBoNTC(Hc) after numerous ion exchange resins and conditions were attempted. The product from
the CM 650 step contained several degradation product of
rBoNTC(Hc) that are faintly seen (lane 2, Fig. 2). Several bands were
transferred from an SDS–PAGE gel, transferred to a PVDF membrane and submitted for sequencing. A fragment of the last 230
amino acids of the rBoNTC(Hc), with a theoretical pI of 6.3 and a
MW of 27 kDa and the ﬁrst 200 amino acids of the rBoNTC(Hc),
with a theoretical pI 5.04 and a MW of 22 kDa were identiﬁed.
The pI of rBoNTC(Hc) is 5.5, making it difﬁcult to remove the fragments by ion exchange. Different types of pH gradients and steps
were attempted to purify away the remaining contaminates with
the HCIC resin but this did not prove effective. Since the HCIC resin
separates by both charge and hydrophobicity a gradient from
25 mM succinate 1 M NaCl buffer at pH 4.0 to a 25 mM succinate,
pH 3.0 buffer, which combined both a pH and ionic strength gradient was tried. This turned out to be very effective in separating the
remaining contaminates (Fig. 2). A total protein load of 5 mg/mL
resin resulted in no rBoNTC(Hc) detected in the ﬂow through and

Fig. 3. (A) SDS–PAGE (reduced) of the product peaks from each step of a pilot run
with an equal total protein load based on BCA. Lane 1, lysate; lane 2, HCIC column 1
product; lane 3, CM 650M product; lane 4, HCIC column 3 product; lane 5, UF/DF
product. (B) SDS–PAGE (reducing) of the ﬁnal product from pilot scale run 2 at
0.5–5 lg loads which are based on an experimental extinction coefﬁcient.

Table 2
Yield from bench-scale puriﬁcation of rBoNTC(Hc).a
Step (product
pool)

Volume
(mL)

Protein conc. (mg/
mL)

Total protein
(mg)

Lysate
HCIC column 1
CM 650M
HCIC column 3
Diaﬁltration

490 ± 5
575 ± 35
750 ± 135
478 ± 68
707 ± 113

5.1 ± 0.9
0.79 ± 0.07
0.41 ± 0.05
0.54 ± 0.10
0.25 ± 0.07

2500 ± 400
456 ± 56
302 ± 46
240 ± 30
171 ± 28

a
Average of four bench-scale puriﬁcation runs starting from 80 g cells wet
weight.
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Table 3
Yield from second pilot-scale puriﬁcation of rBoNTC(Hc).a

a

Step (product pool)

Volume (mL)

Protein conc. (BCA) (mg/mL)

Total protein (mg)

Est. purity (%)

rBoNTC(Hc) (mg)

Step yield (%)

Total yield (%)

Lysate
HCIC column 1
CM 650M
HCIC column 3
Diaﬁltration

5000
9800
13,000
5700
4200

6.82
0.58
0.19
0.38
0.50

34,100
5684
2470
2166
2100

12
70
95
99
99

4092
3979
2347
2144
2079

100
97
59
91
97

100
97
57
52
51

Puriﬁcation is from 1.0 kg cells wet weight.

by collecting most of the elution peak (Fig. 4) it was possible to
separate the degraded rBoNTC(Hc) from the intact rBoNTC(Hc).
After the last chromatography step the HCIC product pool was
dia-ﬁltered with 15 mM succinate, pH 4.0 using a 10 kDa GE
Healthcare hollow ﬁber 5.2 ft2 membrane. This step was used to

raise the pH and reduce the conductivity of the product. The HCIC
elutant is at pH 3.5 with a conductivity of 25–30 mS/cm. SDS–PAGE
of each product pool from each step of the process is presented in
Fig. 3. The Bulk Drug Substance (BDS) is at pH 4.0, conductivity of
1 mS/cm2, protein concentration of 0.5 mg/mL, and by visual

Fig. 4. (A) Bar chart of RP-HPLC results from the 13 week stability study showing that the BDS from the second scale-up run showed little loss at all temperatures based peak
integration. (B) SDS–PAGE (reduced) lanes 1 and 2 – time = 0 BDS; lanes 3 and 4 – 13 weeks at 80 °C; lanes 6 and 7 – 13 weeks at 5 °C; lanes 8 and 9 – 13 weeks at 25 °C.
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Table 4
Potency results of a 24-month stability study of BDS stored at

80 °C.

Time point (months)

ED50 (ng)

95% Conﬁdence limits (ng)

0
3
6
24

102
117
118
66

58–175
76–195
7–691
32–120

inspection of an SDS–PAGE is >98% pure (Fig. 3A – lane 5). The entire puriﬁcation process from cell washing to ﬁnal sterile-ﬁltering
of the BDS at the bench scale was performed within 7 h.
Four bench-scale puriﬁcation runs were performed to determine the robustness of the process. The BDS from these runs were
very similar in purity and elution proﬁles. The yields ranged from
1.7 to 2.5 g of puriﬁed rBoNTC(Hc)/kg WCW (Table 2). The yield
varied based on how the product peak was collected from the ﬁnal
HCIC column, with a conservative ‘‘cut” for the ﬁrst run which was
increased for the second run resulting in a higher yield. Analysis by
N-terminal sequencing showed the rBoNTC(Hc) to have an intact
N-terminus (MYFNNIN) with a N-terminal Methionine, and is identical to the gene sequence of the N-22 form.

Based on these results the potency of the bulk material is stable for
24 months. Biophysical analysis (SDS–PAGE and RP-HPLC) was not
performed past 3 months.
Conclusion
The recombinant heavy chain fragment C of botulinum neurotoxin serotype C was produced from P. pastoris X-33 and puriﬁed
using only MEP HyperCel™ and the CM 650M resins. The process
was scaled-up and resulted in similar product quality at both the
bench and pilot scales. The rBoNTC(Hc) was stable, based on
SDS–PAGE and RP-HPLC when stored at a pH of 4.0 in 15 mM succinate and 0.25–0.5 mg/mL and showed biophysical stability for at
least 3 months at 5 and 80 °C. The product remained potent when
stored at 80 °C for up to 24 months. The puriﬁcation process required three sequential chromatographic steps with no ultraﬁltration steps between and with the bulk formulation step requiring
membrane diaﬁltration to a protein concentration of 0.25–
0.5 mg/mL. The process was easy to scale up with a production
time under 12 h at the pilot scale. The product was intact and comparable in potency to other rBoNT vaccines and ready to be transitioned into cGMP manufacturing.

Pilot-scale puriﬁcation
Two 19 L fermentations and two pilot-scale puriﬁcations runs
were performed. The fermentations resulted in ﬁnal WCW of 254
and 248 g/L with ﬁnal volumes of 12 and 11.7 L, respectively. The
pilot-scale puriﬁcation process from cell washing to bulking of
the BDS took just under 12 h.
The ﬁrst pilot-scale puriﬁcation produced 1.4 g BDS/kg wt cell
mass and was >98% pure based on SDS–PAGE (Fig. 3) with the Nterminal sequence intact (Table 3). A second pilot-scale puriﬁcation generated a >98% pure product based on SDS–PAGE (Fig. 3B),
with a N-terminal sequence intact (MYFNNIN) and produced
2.08 g/kg WCW (Table 3). A residual DNA test was performed on
the ﬁnal product (AppTec, Philadelphia, PA), and was below the
limit of detection (<20 pg DNA/100 lg of rBoNTC(Hc).
Biophysical stability
Stability testing was performed on the ﬁnal product from the
second pilot scale run. This material was put into 15 mL aliquots
and placed at three different temperatures (25, 5 and 80 °C).
Analysis by RP-HPLC and SDS–PAGE were performed at time points
0, 2, 9, and 13 weeks. Fig. 4A shows the amount of intact
rBoNTC(Hc) over the course of the stability study by RP-HPLC.
Based on these assays the rBoNTC(Hc) was stable for at least
3 months at 5 and 80 °C. Protein decreases were seen in the
25 °C sample beginning at 9 weeks. This was conﬁrmed by the degradation bands appearing in the SDS–PAGE (Fig. 4B). These results
show the BDS remained intact for at least 3 months at both 5 and
80 °C.
Mouse potency assay and stability
A mouse bioassay was used to determine rBoNTC(Hc) BDS potency and stability over time. Material from the second pilot scale
run was used for vaccination and a 24-month stability study. Potency assay results showed protection to be centered, with an
ED50 (theoretical effective dose protecting half the mice) of
102 ng, having 95% conﬁdence limits of 58–175 ng (Table 4). The
potency of this rBoNTC(Hc) preparation is roughly equivalent to
potencies of other rBoNT vaccines, which range from 89 to
116 ng [26]. A 24-month potency stability study of material stored
at 80 °C was performed and the results are presented in Table 4.
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